Assistance Publique - Hôpitaux de Paris, département de pathologie, Hôpital Bichat-Claude Bernard, Paris, France.
Department of pathology, AP-HP, Bichat- Hospital, 46 rue Henri Huchard 75877, 18, Paris Cedex, France.
Pathol Oncol Res. 2020 Oct;26(4):2795-2800. doi: 10.1007/s12253-019-00713-1. Epub 2019 Aug 12.
To retrospectively characterize the molecular features of Non-Small Cell Lung Carcinomas (NSCLC) with peritoneal carcinomatosis (PC), clinicopathological data of 12 patients diagnosed with NSCLC and PC between 2007 and 2016 were collected. Immunohistochemistry and Next Generation Sequencing (NGS) were performed on cases with available material. PC was the initial presentation of NSCLC in 17% of the cases. Overall, patients with PC displayed a poor median survival of 12 weeks. Histology was adenocarcinoma in 11 cases. 37.5% of cases showed PD-L1 immunostaining positivity (50% cut-off). ALK and ROS1 immunostainings were negative. Using NGS, we identified 17 molecular alterations in 9 genes (TP53, KRAS, STK11, BRAF, EGFR, DDR2, ERBB4, SMAD4, CTNNB1) in 88.9% of adenocarcinomas. To the best of our knowledge, 5 of these variants are not referenced in the literature. In conclusion, PC might be the initial presentation of NSCLC. Molecular profiling of our cases did not find any effective targetable alteration, except from high PD-L1 expression.
回顾性分析了 2007 年至 2016 年间确诊的 12 例伴腹膜转移的非小细胞肺癌(NSCLC)患者的分子特征。对有可用标本的病例进行免疫组化和下一代测序(NGS)检测。17%的病例以 NSCLC 合并腹膜转移为首发表现。总体而言,PC 患者的中位生存时间为 12 周。组织学上 11 例为腺癌。37.5%的病例 PD-L1 免疫组化染色阳性(50%截点)。ALK 和 ROS1 免疫染色均为阴性。使用 NGS,我们在 88.9%的腺癌中鉴定出 9 个基因(TP53、KRAS、STK11、BRAF、EGFR、DDR2、ERBB4、SMAD4、CTNNB1)中的 17 个分子改变。据我们所知,其中 5 种变异在文献中没有提到。总之,PC 可能是 NSCLC 的首发表现。我们的病例分子谱分析未发现任何有效的靶向治疗改变,除了高 PD-L1 表达。